C4 Therapeutics Q3 2024 Earnings Revenue Surges to 15.4M, GAAP EPS Loss Narrows to 0.35
CCCC Stock | USD 4.55 0.36 8.59% |
About 60% of all C4 Therapeutics' shareholders are looking to take a long position. The analysis of the overall investor sentiment regarding C4 Therapeutics suggests that some traders are interested. The current market sentiment, together with C4 Therapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use C4 Therapeutics stock news signals to limit their universe of possible portfolio assets.
CCCC |
Revenue Reported 15.4 million for Q3 2024, surpassing the analyst estimate of 4.60 million, driven by milestone payments and collaboration agreements.Net Lo
Read at gurufocus.com
C4 Therapeutics Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards C4 Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
C4 Therapeutics Fundamental Analysis
We analyze C4 Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of C4 Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of C4 Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Current Valuation
Current Valuation Comparative Analysis
C4 Therapeutics is currently under evaluation in current valuation category among its peers. Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
C4 Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with C4 Therapeutics stock to make a market-neutral strategy. Peer analysis of C4 Therapeutics could also be used in its relative valuation, which is a method of valuing C4 Therapeutics by comparing valuation metrics with similar companies.
Peers
C4 Therapeutics Related Equities
GLUE | Monte Rosa | 13.72 | ||||
PRLD | Prelude Therapeutics | 7.14 | ||||
IPSC | Century Therapeutics | 5.52 | ||||
NRIX | Nurix Therapeutics | 4.15 | ||||
ARVN | Arvinas | 2.85 | ||||
CGEM | Cullinan Oncology | 2.75 | ||||
FHTX | Foghorn Therapeutics | 2.57 | ||||
EWTX | Edgewise Therapeutics | 2.48 | ||||
RZLT | Rezolute | 1.00 | ||||
STTK | Shattuck Labs | 0.92 | ||||
KYMR | Kymera Therapeutics | 0.02 | ||||
RVMD | Revolution Medicines | 1.25 | ||||
ELYM | Eliem Therapeutics | 1.30 | ||||
MLYS | Mineralys Therapeutics, | 2.59 |
Complementary Tools for CCCC Stock analysis
When running C4 Therapeutics' price analysis, check to measure C4 Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy C4 Therapeutics is operating at the current time. Most of C4 Therapeutics' value examination focuses on studying past and present price action to predict the probability of C4 Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move C4 Therapeutics' price. Additionally, you may evaluate how the addition of C4 Therapeutics to your portfolios can decrease your overall portfolio volatility.
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
Equity Valuation Check real value of public entities based on technical and fundamental data | |
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets |